10
Participants
Start Date
December 16, 2016
Primary Completion Date
April 2, 2019
Study Completion Date
April 2, 2019
Pembrolizumab
200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Decitabine
Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
National Institutes of Health Clinical Center, Bethesda
National Heart, Lung, and Blood Institute (NHLBI)
NIH